LinKinVax operates as a clinical-stage biotechnology company.
LinkinVax has raised €11M across 2 funding rounds from 8 investors, most recently a round in Jan 2023. Based in Paris, France; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount |
|---|
| Investors |
|---|
| 2023-01-10 | Other | €7.3M | André-Jacques Auberton-Hervé,In-Q-Tel | View deal → |
| 2022-02-11 | Seed | €3.8M | Alain Tingaud,André - Jacques Auberton - Hervé,Geoffrey Duyk,Giorgio Anania,Jean-Paul Kress,Rémi Gaston - Dreyfus | View deal → |
